← All trials
NCT05483465
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Aug 31, 2027
- Completion date
- Aug 31, 2027
- First posted
- Aug 2, 2022
- Last posted
- Nov 1, 2022
- Enrollment
- 214
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OklahomaLead sponsor
- Elysium HealthCollaborator
- Oklahoma Medical Research FoundationCollaborator
- University of PennsylvaniaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.